The receptor for advanced glycation endproducts (RAGE) decreases survival of tumor-bearing mice by enhancing the generation of lung metastasis-associated myeloid-derived suppressor cells.

[1]  C. O'brien,et al.  Lysyl Oxidase Like 1: Biological roles and regulation. , 2020, Experimental eye research.

[2]  K. Kessenbrock,et al.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics , 2019, Science Immunology.

[3]  J. Wolchok,et al.  Immunotherapy of Melanoma: Facts and Hopes , 2019, Clinical Cancer Research.

[4]  J. Hoidal,et al.  RAGE is a Critical Mediator of Pulmonary Oxidative Stress, Alveolar Macrophage Activation and Emphysema in Response to Cigarette Smoke , 2019, Scientific Reports.

[5]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[6]  C. Fenselau,et al.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment , 2018, The Journal of Immunology.

[7]  A. Gee,et al.  Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective , 2017, Journal of medicinal chemistry.

[8]  Y. Yamamoto,et al.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis , 2017, Oncogene.

[9]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[10]  Y. Belkaid,et al.  Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche , 2016, Cell.

[11]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[12]  P. Steeg,et al.  Targeting metastasis , 2016, Nature Reviews Cancer.

[13]  Parth Malik,et al.  Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. , 2015, Biochimica et biophysica acta.

[14]  Carsten Denkert,et al.  The landscape of metastatic progression patterns across major human cancers , 2014, Oncotarget.

[15]  K. Tracey,et al.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. , 2014, Cancer research.

[16]  M. Sabbagh,et al.  Effect of TTP488 in patients with mild to moderate Alzheimer’s disease , 2014, BMC Neurology.

[17]  R. Silber,et al.  The receptor for advanced glycation end-products supports lung tissue biomechanics. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[18]  M. Sade-Feldman,et al.  Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. , 2013, Immunity.

[19]  M. Lotze,et al.  The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells , 2013, The Journal of Immunology.

[20]  S. Wong,et al.  Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins , 2013, The Journal of Immunology.

[21]  U. Syrbe,et al.  TNF signaling drives myeloid-derived suppressor cell accumulation. , 2012, The Journal of clinical investigation.

[22]  Kazuyuki Sugahara,et al.  Receptor for Advanced Glycation End Products (RAGE) Functions as Receptor for Specific Sulfated Glycosaminoglycans, and Anti-RAGE Antibody or Sulfated Glycosaminoglycans Delivered in Vivo Inhibit Pulmonary Metastasis of Tumor Cells* , 2012, The Journal of Biological Chemistry.

[23]  Nathan T. Ross,et al.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. , 2012, The Journal of clinical investigation.

[24]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[25]  Derek Marshall,et al.  Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.

[26]  A. Schmidt,et al.  Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling and Up-regulation of Egr-1 in Hypoxic Macrophages* , 2010, The Journal of Biological Chemistry.

[27]  A. Rojas,et al.  Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. , 2010, Carcinogenesis.

[28]  P. Schirmacher,et al.  S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis , 2009, Hepatology.

[29]  P. Nawroth,et al.  Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications , 2009, Diabetologia.

[30]  P. Angel,et al.  The receptor RAGE: Bridging inflammation and cancer , 2009, Cell Communication and Signaling.

[31]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.

[32]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[33]  Steffen Jung,et al.  Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. , 2009, American journal of respiratory and critical care medicine.

[34]  M. Mihm,et al.  Current concepts of metastasis in melanoma. , 2008, Expert review of dermatology.

[35]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[36]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[37]  K. Herold,et al.  RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation1 , 2008, The Journal of Immunology.

[38]  Merlin C. Thomas,et al.  Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.

[39]  A. Enk,et al.  RAGE signaling sustains inflammation and promotes tumor development , 2008, The Journal of experimental medicine.

[40]  S. Vannucci,et al.  Hypoxia-inducible Factor-1 Mediates Neuronal Expression of the Receptor for Advanced Glycation End Products following Hypoxia/Ischemia* , 2007, Journal of Biological Chemistry.

[41]  H. Kubo,et al.  The role of the receptor for advanced glycation end-products in lung fibrosis. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[42]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[43]  J. Wautier,et al.  Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. , 2007, Kidney international.

[44]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[45]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[46]  W. Seeger,et al.  Analysis of tumor vessel supply in Lewis lung carcinoma in mice by fluorescent microsphere distribution and imaging with micro- and flat-panel computed tomography. , 2005, The American journal of pathology.

[47]  D. Foell,et al.  Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[48]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[49]  Y. Hata,et al.  Receptor for advanced glycation end‐products is a marker of type I lung alveolar cells , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[50]  K. Preissner,et al.  The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.

[51]  W. Nacken,et al.  S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity , 2003, Microscopy research and technique.

[52]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[53]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[54]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[55]  B. Nielsen,et al.  A precise and efficient stereological method for determining murine lung metastasis volumes. , 2001, The American journal of pathology.

[56]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[57]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[58]  M. Kuwano,et al.  Biological implications of macrophage infiltration in human tumor angiogenesis , 1999, Cancer Chemotherapy and Pharmacology.

[59]  A. Schmidt,et al.  Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells* , 1998, The Journal of Biological Chemistry.

[60]  M. Müller,et al.  Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. , 1998, Cellular and molecular biology.

[61]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[62]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[63]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[64]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[65]  W. Hurley,et al.  Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.

[66]  S. Barni,et al.  Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. , 1992, Journal of biological regulators and homeostatic agents.

[67]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[68]  E A Zerhouni,et al.  Blood supply of pulmonary metastases , 1987, Journal of thoracic imaging.

[69]  M. Sabbagh,et al.  Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer’s Disease , 2018, The Journal of Prevention of Alzheimer's Disease.